Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N07XX07

Fampridine Accord(Fampridine)

Multiple Sclerosis

Marketing Authorisation Holder: Accord Healthcare S.L.U.

EMA Authorisation: 24/09/2020

INN: fampridine

Indication

Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). 

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Fampridine Accord — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.